TAF Pharmacology

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Less off-target drug exposure with TAF1-6

DESCOVY® contains TAF, which more efficiently delivers tenofovir DP into PBMCs (including lymphocytes like CD4+ T cells) and macrophages vs TDF1-3

Less tenofovir in plasma

Up to 90% reduction of tenofovir levels in plasma with TAF vs TDF4,6

More targeted delivery of active drug

Up to 7x higher mean levels of tenofovir DP in lymphocytes are achieved with TAF vs TDF3,4


TAF Pharmacology TAF Pharmacology
View the DISCOVER Trial

*Plasma half-life: TAF=30 minutes; TDF=0.41 minutes.4
Tenofovir is converted into tenofovir DP in cells.6
DP=diphosphate; PBMC=peripheral blood mononuclear cell (includes CD4+ T cells); TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.